Therapeutic Monoclonal Antibodies

Häftad, Engelska, 1990

Av James W. Larrick, C. Borrebaeck, James W Larrick

1 459 kr

Beställningsvara. Skickas inom 7-10 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

A review of therapeutic antibodies which have commercial potential. It discusses PCR cloning of Igs, immortalization by gene transfer, scale up production, infectious diseases, viruses, bacteria, parisites, inflammation/immunology, blood grouping, cells, cytokines, tumours and MDR.

Produktinformation

Utgivningsdatum1990-01-01
Mått152 x 229 x 22 mm
Vikt562 g
FormatHäftad
SpråkEngelska
Antal sidor369
Upplaga1990
FörlagPalgrave Macmillan
ISBN9781349118960

Tillhör följande kategorier

The use of in vitro immunization, cloning of variable regions and scid mice for the production of human monoclonal antibodies; construction of recombinant therapeutic monoclonal antibodies; antibody-mediated cancer diagnosis and therapy; current status and future perspectives of chemoimmunoconjugates for the treatment of cancer; gangliosides as targets for monoclonal antibody therapy of cancer; mouse antibodies to carcinomas; therapeutic implication of monoclonal antibodies against multidrug resistant tumour cells; radioimmunotherapy with 90yttrium-anti-idiotype monoclonal antibody; immunoconjugates of a protein synthesis inhibiting drug; human monoclonal anti-idiotypic antibodies against a murine monoclonal antibody (Mab17-1A) as an anti-tumour vaccine; uses of human monoclonal antibodies to human cytomegalovirus and varicella-zoster virus; development of a human monoclonal antibody against cytomegalovirus with the aim of passive immunotherapy; characterization of human anti-cytomegalovirus monoclonal antibodies; immunoprotective capacities of human and murine monoclonal antibodies recognizing serotype specific and common determinants of gram-negative bacteria; pharmocokinetics of xomen TM-E5 in animals and humans; radomized placebo-controlled study of E5 monoclonal antiendotoxin antibody; human monoclonal antibodies against human red blood cells; CD7 monoclonal antibodies; large scale production of monoclonal antibodies; European regulatory issues.